安徽安科生物工程(集团)股份有限公司 2025 年半年度报告全文 1 安徽安科生物工程(集团)股份有限公司 2025 年半年度报告全文 安徽安科生物工程(集团)股份有限公司 2025 年半年度报告 公告编号：2025-041 【2025 年 8 月 22 日】 2 安徽安科生物工程(集团)股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人宋礼华、主管会计工作负责人胡成浩及会计机构负责人(会计 主管人员)胡成浩声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中涉及的未来计划等前瞻性陈述不构成公司对投资者的实质承诺， 敬请投资者理性投资，注意风险。 报告期内，公司可能存在新药研发不达预期的风险、行业政策变化及集中 带量采购导致药品降价的风险、业务整合及规模扩大带来的集团化管理风险、 投资项目收益不达预期的风险等，有关风险因素内容详见本报告中第三节"管 理层讨论与分析"之 ...

安科生物公告，2025年上半年营业收入12.92亿元，同比下降0.51%。净利润3.67亿元，同比下降 11.92%。 ...

Group 1 - The assisted reproductive concept sector declined by 0.81%, ranking among the top declines in concept sectors, with major declines seen in companies like Fuyuan Pharmaceutical, Guangsheng Tang, and Wanfu Biology [1][2] - Among the 59 stocks in the assisted reproductive sector, 23 stocks saw price increases, with notable gains from Toukeng Life (up 7.45%), ST Xiangxue (up 4.55%), and Sichuan Shuangma (up 3.55%) [1][2] - The assisted reproductive sector experienced a net outflow of 2.015 billion yuan in main funds, with Guangsheng Tang leading the outflow at 297.48 million yuan [2][3] Group 2 - The top stocks with net outflows in the assisted reproductive sector included Guangsheng Tang, Hanyu Pharmaceutical, and Fuyuan Pharmaceutical, with outflows of 297.48 million yuan, 212.23 million yuan, and 164.10 million yuan respectively [2][3] - Conversely, the stocks with the highest net inflows included Wuchan Zhongda, Sichuan Shuangma, and Xianju Pharmaceutical, with inflows of 59.78 million yuan, 52.71 million yuan, and 36.47 million yuan respectively [2][4] - The overall trading activity in the assisted reproductive sector showed significant turnover rates, with Guangsheng Tang at 12.48% and Hanyu Pharmaceutical at 19.69% [2][3]

截至8月20日收盘，肝炎概念下跌0.67%，位居概念板块跌幅榜前列，板块内，新天药业、诚意药业等 跌停，广生堂、维康药业、万孚生物等跌幅居前，股价上涨的有52只，涨幅居前的有仁和药业、方盛制 药、立方制药等，分别上涨10.00%、9.99%、4.76%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 同花顺果指数 | 3.70 | 猴痘概念 | -0.86 | | AI手机 | 2.77 | 重组蛋白 | -0.85 | | 国家大基金持股 | 2.76 | 辅助生殖 | -0.81 | | MCU芯片 | 2.60 | 高压氧舱 | -0.68 | | 丙烯酸 | 2.56 | 肝炎概念 | -0.67 | | 智能音箱 | 2.55 | CRO概念 | -0.64 | | AI眼镜 | 2.54 | 细胞免疫治疗 | -0.60 | | 白酒概念 | 2.40 | 华为盘古 | -0.56 | | 金属锌 | 2.39 | 中船系 | -0.55 | | 汽车芯片 | 2.39 | 仿制药一致性评价 | ...

证券之星消息，8月19日生物制品板块较上一交易日上涨0.27%，欧林生物领涨。当日上证指数报收于 3727.29，下跌0.02%。深证成指报收于11821.63，下跌0.12%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688319 | 欧林生物 | 31.21 | 12.71% | 27.56万 | | 8.31亿 | | 430047 | 诺思兰德 | 28.44 | 11.53% | 21.17万 | | 6.22亿 | | 603087 | 甘李药业 | 68.03 | 6.95% | 40.61万 | | 27.93亿 | | 837344 | 三元基因 | 32.65 | 6.53% | 7.51万 | | 2.50亿 | | 002581 | ST未名 | 7.69 | 5.05% | 10.63万 | | 8072.66万 | | 688687 | 凯因科技 | 38.59 | 4.95% | 13.46万 | | 5.24亿 ...

新华财经上海8月18日电 A股进入中报密集披露期，公募调研热情攀升。据公募排排网数据显示，上周 （2025年8月11日-8月17日）共有139家公募机构参与到A股调研活动中，覆盖到20个申万一级行业中的66 只个股，合计调研次数达729次，较前一周环比增幅46.39%。 行业方面，上周医药生物行业最受公募调研青睐，该行业中高达10只个股受到公募调研青睐，合计被调 研次数达151次，无论是被调研个股数量还是调研次数，均明显领先于其余行业。其次是计算机行业，该 行业中有4只个股受到公募调研关注，合计被调研次数达100次。 电子、电力设备、基础化工和美容护理亦受到公募机构调研关注，均被调研不少于50次，排名前十。 机构方面，上周鹏华基金以20次调研居首，覆盖11个行业的19只个股，电力设备、电子及基础化工行业 个股占比相对较高；国泰基金与南方基金均以14次调研并列第二，国泰基金聚焦8个行业的14只个股，医 药生物行业个股数量占优，南方基金则覆盖10个行业的14只个股，电子、计算机、电力设备及基础化工 行业个股相对较多。 （文章来源：新华财经） 个股方面，上周美容护理行业龙头百亚股份被公募机构调研达53次居首，同时也 ...

Group 1 - The innovation drug concept remains active, with significant market movements and various sectors showing strong performance, particularly in the financial and innovation drug sectors [1] - The estimated market size for China's innovative drug and medical device market in 2024 is approximately 162 billion yuan, with predictions to exceed 1 trillion yuan by 2035 [1] - Multiple innovative drug ETFs have seen substantial inflows, with a total net inflow of 7.551 billion yuan in August, indicating strong investor interest [2] Group 2 - Over 80 innovative drug concept stocks have seen an average price increase of 4.42% since August, with some stocks like Nanmo Biology and Shunlian Bio rising over 40% [3] - Nanmo Biology has experienced the highest price increase of 97.5% in August, driven by its advanced technology platform for gene research [3] - Several innovative drug stocks, including Borui Pharmaceutical and Anke Bio, have received significant institutional attention, with over 10 institutions conducting research on them [4] Group 3 - Borui Pharmaceutical has signed a strategic cooperation agreement with Hanyu Pharmaceutical, enhancing its supply capabilities for future product launches [4] - Anke Bio has reached a nationwide exclusive agency agreement for a new innovative drug, which is expected to be the first long-acting follicle-stimulating hormone preparation in China [4] - More than half of the innovative drug concept stocks have received net buying from financing, with notable amounts for companies like WuXi AppTec and Borui Pharmaceutical [4]

Group 1 - The innovative drug concept remains active, with the market showing strong performance, as the Shanghai Composite Index surpassed 3731.69 points, a nearly 10-year high [1][3] - The innovative drug market in China is estimated to reach approximately 162 billion yuan in 2024, with a projected market size exceeding 1 trillion yuan by 2035 [3][4] - Multiple innovative drug ETFs have attracted significant capital inflow, with a total net inflow of 7.551 billion yuan in August alone [4] Group 2 - Over 80 innovative drug concept stocks have seen an average price increase of 4.42% since August, with notable performers like Nanmo Biology and Shunlian Bio rising over 40% [7] - Institutions have shown strong interest in several innovative drug stocks, with 90 institutions conducting research on Borui Pharmaceutical, which has signed a strategic cooperation agreement with Hanyu Pharmaceutical [7][10] - More than half of the innovative drug concept stocks have received net buying in financing since August, with major inflows seen in companies like WuXi AppTec and Borui Pharmaceutical [8]

Group 1: Company Overview and Investor Relations - The investor relations activity involved a telephone conference with over 130 participants from various financial institutions [2][3]. - Key personnel included the Chairman and Senior Vice President of the company, who addressed investor inquiries [3]. Group 2: Product Development and Clinical Trials - The "AK1012 project" for treating respiratory syncytial virus infections has completed Phase I clinical trials [3]. - "AK2017 injection" has successfully completed Phase II clinical trial enrollment, with discussions for Phase III trials underway [3]. - "HuA21 injection," targeting HER2, has completed Phase Ib/II clinical trials and is preparing for Phase III based on interim analysis [3][10]. - "AK2024 injection," another HER2-targeted drug, has received clinical approval and shows promising preclinical results [3]. - "HK010 injection," a dual-target PD-L1*4-1BB antibody, is progressing well in Phase I trials [3]. Group 3: Collaborations and Innovations - Collaboration with Afana Company on "AFN0328 injection" for HPV precancerous lesions is in Phase I trials, with plans for further mRNA drug development [4]. - The company’s affiliate, Boshengji, has developed the first CAR-T cell therapy targeting CD7, which has been included in a list of breakthrough therapies by the CDE [4][9]. - The "recombinant L-IFN adenovirus injection" developed by Yuansong Bio has received clinical trial approvals from both CDE and FDA for advanced solid tumors [4]. Group 4: Market Potential and Strategic Partnerships - The long-acting growth hormone "Transcon" is expected to outperform existing products, with a significant market opportunity projected at over 4 billion CNY in 2025 for follicle-stimulating hormone [8]. - The partnership with Baoyi Pharmaceutical for "SJ02," a long-acting follicle-stimulating hormone, aims to enhance treatment options in assisted reproductive technology [8]. - The PA3-17 injection has shown an objective response rate (ORR) of 84.6% and a complete remission rate of 95% in clinical trials [9]. Group 5: Future Plans and Regulatory Compliance - The company is actively building production lines compliant with FDA and EU standards, aiming for international market commercialization [11]. - Future clinical plans include launching Phase II trials for PA3-17 and exploring international registration based on Chinese clinical data [9].

Core Insights - The article highlights the top 20 stocks experiencing significant outflows of main capital as of August 12, with notable amounts for each company [1] Group 1: Major Capital Outflows - Northern Rare Earth saw an outflow of 0.702 billion yuan [1] - Tianqi Lithium experienced a capital outflow of 0.545 billion yuan [1] - Great Wall Military Industry had an outflow of 0.531 billion yuan [1] - Jinfeng Technology faced a capital outflow of 0.522 billion yuan [1] - Aerospace Science and Technology saw an outflow of 0.498 billion yuan [1] - Shenghe Resources experienced a capital outflow of 0.486 billion yuan [1] - AVIC Shenyang Aircraft Company had an outflow of 0.466 billion yuan [1] - Jihua Group faced a capital outflow of 0.420 billion yuan [1] - China Rare Earth experienced an outflow of 0.350 billion yuan [1] - Hezhong Electric saw an outflow of 0.346 billion yuan [1] - Sino Medical Sciences experienced a capital outflow of 0.343 billion yuan [1] - Huasheng Tiancheng faced an outflow of 0.338 billion yuan [1] - Xingsen Technology saw an outflow of 0.329 billion yuan [1] - Tuolisi experienced a capital outflow of 0.320 billion yuan [1] - Inner Mongolia First Machinery Group had an outflow of 0.295 billion yuan [1] - Jingwang Electronics faced an outflow of 0.290 billion yuan [1] - Northern Navigation experienced a capital outflow of 0.285 billion yuan [1] - Ganfeng Lithium saw an outflow of 0.257 billion yuan [1] - Anke Biotechnology faced an outflow of 0.250 billion yuan [1] - Baogang Group experienced a capital outflow of 0.243 billion yuan [1]